eurofins-cdmo_img-0290

Eurofins CDMO Alphora supports the development and manufacturing of monoclonal antibodies (mAbs) with upstream, downstream, analytical, and GMP capabilities on a single North American campus. Whether your program is at research, IND‑enabling, or early clinical stages, our team helps streamline CMC execution while maintaining scientific rigor, clear communication, and alignment with regulatory expectations.

Our capabilities scale seamlessly from early-stage development to commercial manufacturing, supporting processes from small-scale batches to 2,000L single-use bioreactors, including perfusion systems up to 500L.

Leveraging a fully integrated single-use GMP production train, our experienced team delivers flexible, high-quality biologics manufacturing solutions designed to meet diverse client requirements efficiently and reliably.

eurofins-cdmo_img-0579

Upstream development and optimization

Using our deep understanding of CHO and HEK cell lines, our experts design and optimize cell culture processes that maximize viable cell density, productivity, and product quality.

We apply Design of Experiments (DoE) methodologies to build robust, data‑driven process models that scale predictably. Single‑use upstream trains help minimize contamination risks and simplify process transitions as programs advance.

Expand_img

Key capabilities 

  • Fed‑batch and perfusion process development
  • Media, feeds, and process‑parameter optimization
  • Growth media optimization - maximize titre and maintain consistent performance across scales
  • High‑throughput screening for growth and productivity
  • Cell physiology and metabolite analysis
  • Early‑stage benchtop to pilot‑scale transition planning
eurofins-cdmo_img-0452

Downstream processing (DSP)

Our downstream team brings extensive experience purifying a wide range of mammalian‑based biologics—including mAbs, bispecifics, Fc‑fusion proteins, recombinant proteins, exosomes/VLPs, and payload‑bearing intermediates.

Each purification strategy is developed with scalability, impurity control, and manufacturability in mind, ensuring a smooth path from pilot‑scale results to GMP execution.

Expand_img

DSP Expertise

  • Multi‑step chromatography development
  • Resin screening and buffer condition mapping
  • Filtration, depth filtration & nanofiltration development
  • UF/DF optimization for targeted concentration & diafiltration
  • Process robustness, hold‑time, and impurity‑clearance studies
eurofins-cdmo_img-0528

Process development & scale-up

Our development scientists support efficient scale‑up using integrated single‑use technologies designed to reduce contamination risk and streamline transitions from development to GMP manufacturing.

This structured approach ensures that cell culture performance, purification behavior, and analytical methods transfer cleanly between scales.

Expand_img

Capabilities

  • DoE‑based scale‑up strategies
  • Risk Group 2 biologics handling (e.g., mAbs, ADC intermediates, exosomes, VLPs, recombinant proteins)
  • Automated small‑scale development to larger pilot‑scale operations
  • Technology transfer to clinical manufacturing
eurofins-cdmo_img-0290

Analytical development & support

Our analytical team provides phase‑appropriate testing and method development to support upstream and downstream workflows.

Analytical readiness is integrated early in development to ensure smooth progression into GMP manufacturing.

Expand_img

Services

  • Analytical method development & qualification
  • GMP method validation
  • Release testing & stability studies
  • Product characterization, including identity, purity, and quality attributes
  • Lifecycle management of analytical methods
  • Bioassays
adobestock_406563523

GMP manufacturing

Our 2000 L GMP production train enables clinical and commercial manufacturing.

Our GMP biologics suites are designed for flexibility, batch consistency, and efficient changeover across varying program types.